SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 8

Outcomes of Sorafenib Therapy in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A 12-Year Single-Center Experience

Abdülkerim Duran(AKDENIZ UNIVERSITY, FACULTY OF MEDICINE)0000-0001-7830-2277
Özen Öz Gül(BURSA ULUDAG UNIVERSITY)0000-0002-1332-4165
Soner Cander(BURSA ULUDAG UNIVERSITY)0000-0001-6303-7896
Ahmet Bilgehan Şahin(BURSA ULUDAG UNIVERSITY)0000-0002-7846-0870
Pages
—
Publication Date
2026-02-28
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Progression-free survival (PFS), overall survival (OS), response rates, and adverse events profiles were analyzed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Differentiated thyroid cancer (DTC) generally has a favorable prognosis; however, resistance to radioactive iodine therapy (RAI) markedly worsens outcomes.
📊
Key Findings & Data:Methods: The medical records of patients diagnosed with RAI-refractory DTC who were followed in the endocrinology and oncology outpatient clinics of Bursa Uludağ University Faculty of Medicine Hospital between 2010 and 2022 and treated with sorafenib were retrospectively reviewed.
💡
Conclusion & Impact:Progression-free survival (PFS), overall survival (OS), response rates, and adverse events profiles were analyzed.
🔬Design:Review & Systematic Survey
📍Scope:2010 Verileri
⚙️Variables:Radioactive iodine-resistance · Differentiated thyroid cancer · Sorafenib

Abstract

Objective: Differentiated thyroid cancer (DTC) generally has a favorable prognosis; however, resistance to radioactive iodine therapy (RAI) markedly worsens outcomes. Sorafenib is among the standard treatment options for RAI-refractory DTC. This study aimed to present our single-center experience with sorafenib therapy. Methods: The medical records of patients diagnosed with RAI-refractory DTC who were followed in the endocrinology and oncology outpatient clinics of Bursa Uludağ University Faculty of Medicine Hospital between 2010 and 2022 and treated with sorafenib were retrospectively reviewed. Progression-free survival (PFS), overall survival (OS), response rates, and adverse events profiles were analyzed. Results: Of the 19 patients included, 68.4% had papillary thyroid carcinoma and 31.6% had follicular variants. Median PFS was 16.1 months, and median OS was 36.2 months. The overall response rate was modest, while sorafenib-related adverse events occurred in 63% of patients, most commonly hand–foot syndrome (31%). Conclusion: Our single-center data suggest that sorafenib is a generally tolerable and effective therapeutic option in patients with RAI-refractory DTC, with median PFS exceeding 1 year despite frequent adverse events.

🔖

Cite This Article

Duran, A., Gül, Ö. Ö., Cander, S., Şahin, A. B. (2026). Outcomes of Sorafenib Therapy in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A 12-Year Single-Center Experience. Turkish Journal of Internal Medicine, Volume: 8. https://doi.org/10.46310/tjim.1816052

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. WHO GLOBOCAN 2022 [cited 2025 Aug 5]. Available from: https://gco.iarc.who.int/.
  2. Asa SL. The current histologic classification of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):1– 22. doi:10.1016/j.ecl.2018.10.001.
  3. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism. 2006;91(8):2892–9. doi:10.1210/jc.2005-2838.
  4. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine. 2015;372(7):621–30. doi:10.1056/ NEJMoa1406470.
  5. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet. 2014;384(9940):319–28. doi:10.1016/S0140-6736(14)60421-9.
  6. Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, et al. 2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35(8):841–985. doi:10.1177/10507256251363120.
  7. NCCN. Thyroid Cancer 2025 [cited 2025 Oct 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
  8. Oh HS, Shin DY, Kim M, Park SY, Kim TH, Kim BH, et al. Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study. Thyroid. 2019;29(12):1804–10. doi:10.1089/thy.2019.0246.
  9. Yekedüz E, Köksoy EB, Çay Şenler F, Akbulut H, Demirkazık A, Ürün Y, et al. Sorafenib in radioactive iodine refractory differentiated thyroid cancer: a real-life data with long-term experience. Journal of Ankara University Faculty of Medicine. 2022;75(1):103–6. doi:10.4274/atfm.galenos.2021.24572.
  10. Lin CY, Chang JS, Huang SM, Hung CJ, Hung CL, Chang CT, et al. Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan. Journal of the Formosan Medical Association. 2021;120(1):189–95. doi:10.1016/j.jfma.2020.04.021.
  11. Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, et al. Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study. Thyroid. 2018;28(3):340–8. doi:10.1089/thy.2017.0356.